Lantern Pharma (LTRN) announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 Harmonic clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer who have progressed after receiving treatment with tyrosine kinase inhibitors.
Education
About Us
Working with TipRanks
Follow Us
